Philadelphia, Pennsylvania--(Newsfile Corp. - April 8, 2024) - Current Inspire Medical shareholders who have continuously held Inspire Medical (NYSE: INSP) shares since prior to May 3, 2023, can seek corporate reforms, the return of funds back to company coffers, and a court approved incentive award at no cost to them whatsoever. Click https://grabarlaw.com/the-latest/inspire-medical-shareholder-investigation/.
Grabar Law Office is investigating claims on behalf of Inspire Medical Systems, Inc. (NYSE: INSP) shareholders. The investigation concerns whether certain officers of Inspire Medical have breached their fiduciary duties owed to the company.
BASIS OF THE INVESTIGATION: A recently filed securities fraud class action complaint alleges that Inspire Medical Systems, Inc. (NYSE: INSP), via certain of its officers and directors, misled investors and/or failed to disclose that: (1) despite the Company's Acceleration Program, customers were encountering challenges with the prior authorization submission process, including with the scheduling of appointments; (2) a slowdown in prior authorization submissions arising from these challenges led to a shortfall of hundreds of procedures to implant the Company's OSA device; and (3) as a result, Defendants' positive statements about the Company's financial guidance, business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
WHAT TO DO NOW: If you would like to learn more about this matter,you are encouraged to visithttps://grabarlaw.com/the-latest/inspire-medical-shareholder-investigation/, contact Joshua H. Grabar at jgrabar@grabarlaw.com or Mia R. Heller at mheller@grabarlaw.com, or call 267-507-6085.
$INSP #InspireMedical
Attorney Advertising Disclaimer
Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: jgrabar@grabarlaw.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/204689
